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Summary 
PrEP (Pre-Exposure Prophylaxis) is a relatively new drug-based HIV prevention technique and an 
important means to lower the HIV risk of gay men who are especially vulnerable to HIV. From 
the perspective of biopolitics, PrEP inscribes itself in a larger trend of medicalization and the rise 
of pharmapower. This article reconstructs and evaluates contemporary literature on biopolitical 
theory as it applies to PrEP, by bringing it in a dialogue with a mapping of the political debate on 
PrEP. As PrEP changes sexual norms and subjectification, for example condom use and its mean-
ing for gay subjectivity, it is highly contested. The article shows that the debate on PrEP can be 
best described with the concepts ‘sexual-somatic ethics’ and ‘democratic biopolitics’, which I de-
velop based on the biopolitical approach of Nikolas Rose and Paul Rabinow. In contrast, interpre-
tations of PrEP which are following governmentality studies or Italian Theory amount to either 
farfetched or trivial positions on PrEP, when seen in light of the political debate. Furthermore, the 
article is a contribution to the scholarship on gay subjectivity, highlighting how homophobia and 
homonormativity haunts gay sex even in liberal environments, and how PrEP can serve as an entry 
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point for the destigmatization of gay sexuality and transformation of gay subjectivity. ‘Biopolitical 
democratization’ entails making explicit how medical technology and health care relates to sexual 
subjectification and ethics, to strengthen the voice of (potential) PrEP users in health politics, and 
to renegotiate the profit and power of Big Pharma. 
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1 Introduction: PrEP and Biopolitics 
PrEP (Pre-Exposure Prophylaxis) is a relatively new means to prevent HIV infections. HIV nega-
tive people take antiviral drugs which inhibit an exposure to the virus from leading to infection. In 
contrast to condom-use, this prevention technique is based on medical drugs, and not on a change 
in behavior. From the perspective of biopolitics, it inscribes itself in a larger trend of medicaliza-
tion, the rise of pharmapower, and the governmentalization of risk. From this perspective, the in-
vention of this new technology produces new demands on individuals – as such it is a form of 
power. The main target group of PrEP are gay men who are especially vulnerable to HIV, while 
the question of which subgroup of gay men should be advised to take PrEP is subject to medical 
debates. Sexual behavior is a result of subjectification, the process through which social norms 
form subjects and their desires. The medicalization of sex through PrEP changes sexual subjecti-
fication and therefore goes hand in hand with a change of gay sex practices. Where the condom 
was the unquestioned means for safe sex, in the age of PrEP, it is technically not necessary any-
more. Many gays embrace the new possibility to engage in condomless and safe sex. But the more 
people take PrEP, the more there is a change of sexual norms towards condomless sex, which 
might pressure individuals to go on PrEP. 
After briefly elaborating on the medical specificities and history of PrEP (1), this chapter brings 
together a reconstruction of contemporary theoretical approaches to bio-politics related to PrEP 
(2) with a mapping of current political debates around PrEP (3). The investigation shows that 
3 
Governmentality Studies and Italian Theory1 focus on repressive power structures and therefore 
cannot account for the complexity of the debate, which stems from the subjectivity and agency of 
different actors involved, especially gay PrEP activists. Nevertheless, interpretations of PrEP as 
repressive power are also used by some actors in the political debate about PrEP, mostly without 
explicit reference to biopolitical theory. Nikolas Rose’s and Paul Rabinow’s nuanced accounts of 
biopolitics offer some tools to describe the debate around PrEP and the complex negotiation of 
sexuality which it involves, like biopolitical citizenship and somatic ethics. I draw on these ideas 
to develop a new concept of the ‘democratic biopolitics’ of PrEP, which enables a further democ-
ratization of sexuality in a biopolitical age. 
Moreover, the chapter discusses PrEP and the problems associated with it from a perspective of 
queer and gay theory, contributing to the scholarship about gay subjectivity. While public health 
discourse tries to avoid identity categories because of their well-documented exclusionary and 
repressive functions, I mostly use the term ‘gay’ and not ‘men who have sex with men’, for two 
reasons. First, because ‘homosexual’ PrEP users mostly identify as gay, as a self-perception of 
being vulnerable to HIV which is connected to gay identity is mostly motivating to take it. Second, 
because the debate around PrEP is in part a political negotiation of gay identity, i.e., it is a negoti-
ation of what it means to be gay and ‘good’ gay sexual ethics.2 While the chapter maps the political 
debate around PrEP and accounts for both pro-PrEP and anti-PrEP positions, it shows that PrEP is 
effective not only for HIV prevention, but also for fighting homophobia and enhancing the quality 
of life for gays by destigmatizing gay sex. 
 
                                                 
1 Italian Theory is a label for contemporary Italian approaches of political theory, represented by Giorgio Agamben, 
Antonio Negri, Paolo Virno, and Roberto Esposito, among others, cf. Pasquinelli (2011). 
2 Race, especially in the U.S., is a crucial factor in the HIV epidemic. African Americans have higher HIV rates than 
other racial minorities and Whites, with Black men who have sex with men (MSM) being the most vulnerable group: 
“Gay and bisexual men continue to be most affected by the HIV epidemic in the U.S. At current rates, 1 in 6 MSM 
will be diagnosed with HIV in their lifetime, including 1 in 2 black MSM, 1 in 4 Latino MSM, and 1 in 11 white 
MSM. African Americans are by far the most affected racial or ethnic group with a lifetime HIV risk of 1 in 20 for 
men (compared to 1 in 132 for whites) and 1 in 48 for women (compared to 1 in 880 for whites)” (CDC 2016). Many 
Black American MSM do not identify as gay or bisexual, as U.S. gay mainstream culture is predominantly White. 
The complex reasons for the extreme epidemic of Black gays or non-gay-identifying MSM and the difficult attempts 
to bring PrEP to their communities is beyond the scope of this article (Villarosa 2017). With its focus on the main-
stream gay debate in the global north, this chapter is effectively dominated by White perspectives. 
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2 PrEP – The Medicalization of HIV Prevention 
Pre-Exposure Prophylaxis (PrEP) is a medical HIV prevention technique. It refers to anti-retroviral 
(ARV) drugs taken by HIV-negative individuals in order to avoid an infection in case they come 
in contact with the virus. Studies show that PrEP is highly effective, with a protection level of 
about 92 percent when taken as one pill daily (Grant et al. 2010; Spinner et al. 2016; McCormack 
et al. 2016).3 This is a protection efficacy than reached through condoms, the classical behavioral 
prevention technique, which is around 70 percent for men who have sex with men (MSM) (Smith 
et al. 2015; Ryan 2015). PrEP is not necessarily a complete alternative to behavioral prevention 
methods such as condom use or serosorting4, but often used alongside with these methods as an 
additional means of prevention. Currently, the only drug which is certified for PrEP-use is 
Truvada, but other oral drugs such as Descovy (AVAC 2018) and forms such as vaginal gel are 
currently being tested in studies. Truvada has also been tested in an ‘on demand’ scheme, which 
involves only taking the drug shortly before and after a risk of infection, which showed lower rates 
of protection than the daily regime (Molina et al. 2015; Cousins 2017). 
Truvada stops the reproduction of the HI-virus in the cells of a person exposed to HIV, so that this 
person does not get infected. Infection occurs through a process called reverse-transcriptase, where 
the virus copies its own RNA into the DNA of the infected cell, leading to a production of new 
viruses through the infected host cell. Truvada is a reverse-transcriptase inhibitor (RTI), which 
prevents this reproduction process by changing enzymes which are needed for copying the RNA 
into the host cell’s DNA. 
PrEP can be located within a broader trend towards the medicalization of HIV prevention and 
sexuality (Cacchioni and Tiefer 2012). Classical prevention was behavioral, advertising to use 
condoms, to refrain from certain sex practices, or from sex altogether. In contrast to behavioral 
prevention, medical prevention minimizes infection through the administration of drugs (Giami 
and Perrey 2012). Other technologies of medical prevention which preceded PrEP are Treatment 
                                                 
3 The protection efficacy refers to the difference of the risk of HIV transmission per sex act between using no protec-
tion and the respective protection technology (PrEP, condom, serosorting, etc). 
4 Serosorting refers to choosing sexual partners according to their serostatus, for example if an HIV-positive person 
has sex with an HIV-positive partner. 
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as Prevention (TasP) and Post-Exposure Prophylaxis (PEP) (Cohen et al. 2013; Forsyth and Val-
diserri 2012; Cohen et al. 2012; Sultan et al. 2014). TasP involves lowering the virus load of HIV 
positive patients by anti-retroviral (ARV) drugs so that they are not infectious anymore. PEP refers 
to an emergency regime of ARV drugs after a (potential) exposure, which has to begin immediately 
after the exposure in order to be efficient and, contrary to PrEP, comes with significant side effects 
due to a different combination of drugs. The crucial difference between behavioral and medical 
prevention is the timing of the prevention act. Behavioral prevention requires making a preventa-
tive decision while engaging in sexual activity, whilst the conscious act of prevention (taking a 
pill) is decoupled from the sexual act in medical prevention. 
Truvada was first approved for the use as PrEP by the FDA in the United States of America in 
2012 and was made widely available through private health insurances, which makes access easy 
for economically privileged people, and difficult for those without sufficient health care plans. In 
Europe, public and private health insurances were slower to cover for PrEP. The costs of about 
900 EUR per month remained a crucial problem until the patent of Truvada ran out in most Euro-
pean countries in July 2017 (Medical Express 2018; Boulet 2018).5 Countries of the global south, 
especially India, have been producing generics of Truvada and other HIV drugs for many years, 
engaging in legal battles about patents, in order to fight HIV epidemics in their countries. Many 
European gays, for whom PrEP was until recently not covered by their health care systems, ordered 
cheap Truvada-generics from India or Thailand, and often used it without professional supervision. 
PrEP became covered by health care systems in all West-European countries except for Germany 
and Austria in the last two years. Upon writing this chapter, the German health minister announced 
that PrEP would be covered by public health care for vulnerable groups (Redaktion Deutsches 
Ärzteblatt 2018). 
 
3 The Biopolitical Lens 
Biopolitics is a concept coined by Michel Foucault, which he develops in The History of Sexuality 
I (Foucault 1978) and the Governmentality Lectures (Foucault 2007, 2010). Here, Foucault argues 
                                                 
5 In the United States, the patent on Truvada is still protected and affordable generics are not available yet, cf. Land-
man (2017). 
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that modern governmentality operates through a specific kind of power over life, which governs 
both the individual and the collective. On the individual level, biopolitics operates through disci-
plinary power, which Foucault analyzed in his earlier Discipline and Punish (Foucault 1977). On 
the collective level, biopolitics is the regulation of the population through scientific knowledges, 
such as demography and statistics. Biopolitics connects these two levels of power: “The disciplines 
of the body and the regulations of the population constituted the two poles around which the or-
ganization of power over life was deployed” (Foucault 1978, S. 139). Foucault famously distin-
guishes biopolitics or biopower6 from sovereign power, the “right to take life or let live”, which 
was complemented by the biopolitical “right to make live and to let die” (Foucault 2003, S. 241). 
This differentiation is a description of the historical shift towards modern governmentality. The 
old sovereign power had the right to take individual lives, and otherwise leave them alone and 
unregulated (“let live”). Modern biopolitics is an extension and intensification (Nealon 2008) of 
power, insofar as it attempts to productively regulate the population (make live) and thereby gov-
erns many aspects of daily life which were beyond the focus of sovereign power, such as sexuality, 
health, and lifestyles. 
Foucault’s concept of biopolitics proved to be enormously productive, spurring the development 
of whole fields of research.7 In order to critically analyze PrEP through a biopolitical lense, I 
propose to map the debate about biopolitics as follows. Biopolitics on the one had is used as an 
evaluative concept of social critique, and on the other hand as a nuanced analysis of contemporary 
developments. The evaluative use of biopolitics can be further split up into two sub-strands: First, 
biopolitics is a central concept for governmentality studies which draw on Foucault’s non-norma-
tive approach of genealogical critique (Saar 2007) to analyze and criticize contemporary govern-
mentality. Second, accounts of biopolitics form an integral part of the contemporary grand narra-
tives of modernity in Italian Theory, represented by Giorgio Agamben, Antonio Negri, and Rob-
erto Esposito. The nuanced analysis of biopolitics is represented Nikolas Rose and Paul Rabinow. 
                                                 
6 Foucault does not differentiate systematically between biopolitics and biopower. 
7 For a general overview see Lemke (2011); Mills (2018). 
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In what follows, I will briefly elaborate on these three strands, in order to reconstruct positions on 
PrEP which are or could be articulated in their respective frameworks.8 
Governmentality Studies. Governmentality is a concept coined by Foucault which is closely linked 
to biopolitics. Governmentality describes three related aspects: First, the form of modern govern-
ment which has the population as its object (and can be insofar understood to be synonymous with 
biopolitics) and is based on governmental knowledges and rationalities, second the historical ten-
dency towards this governmentality in the West, and third the result of that process, the modern 
administrative state which is governmentalized (Foucault 2007, 108f.). More precisely, govern-
mentality is “liberal” governmentality, and Foucault described its genealogy until the formation of 
contemporary neo-liberalism, in which the market is taken as a natural object which nevertheless 
relies on specific subjectification and regulation (Foucault 2010). Governmentality studies follow 
up on Foucault’s analysis and examine different aspects of neoliberal governmentality with the 
aim of exposing the repressive sides of neo-liberal governmentality and the subjectifications it 
produces (Bröckling et al. 2011a, 2011b; Burchell et al. 1991; Dean 1999; Lemke 2008; Nilsson 
2013). Where neoliberal government proclaims freedom, critical governmentality studies analyze 
normalization and control through subjectification as self-responsible and accountable, which en-
courages subjects to behave like rational homines economici throughout their lives (Bröckling 
2013).9 
While PrEP has hardly been discussed by scholars of governmentality studies, Tim Dean’s Medi-
ated intimacies: Raw sex, Truvada, and the biopolitics of chemoprophylaxis (Dean 2015a) remains 
one of the few examples of how the critical hermeneutics of governmentality studies can be used 
to analyze PrEP. Dean focuses on PrEP’s potentially (or actually) repressive effects and analyzes 
it as an element of broader changes in contemporary governmentality and biopolitics, medicaliza-
tion and the discourse of prevention, which stresses individual responsibility and rational decision 
making. He asks what is biopolitically at stake in PrEP and describes it as an encouragement and 
imperative through “pharmaceutical power” which mediates gay men’s erotic lives (Dean 2015a, 
                                                 
8 The labeling is used here to broadly map the field. The specific positions on HIV and PrEP which I label with the 
sub-strands or schools do not fully capture the positions of these schools. While the arguments regarding PrEP which 
I reconstruct are typical for the three respective schools, different arguments could be constructed through their com-
plex frameworks. 
9 See Schubert (2018, S. 104–111) for a critique of the anti-normativism in contemporary governmentality studies. 
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S. 232). PrEP, according to Dean, is a typical instantiation of biopolitics, which aims at “control 
over populations increasingly through practices of health and wellness. […] Biopower persuades 
us that it is in our own best interests to regulate diet, exercise, and pharmaceutical intake so as to 
optimize our overall health” (Dean 2015a, S. 233). PrEP is part of “normalizing health policies” 
(Dean 2015a, S. 233) and entails close monitoring of gay bodies by medical authorities, which, 
according to Dean, should be refused because it is a form of government: “Nobody wants to be 
told by a government agency how they may have sex” (Dean 2015a, S. 233). Taking resistance 
against PrEP in the gay community as point of departure, Dean argues that it produces “biopolitical 
side-effects (in addition to physiological ones) to mass compliance with pharmaceutical mandates” 
which should be considered (ital. in original, Dean 2015a, S. 234). 
Dean’s criticism can be summarized on two accounts. First, he criticizes the dogmatically biomed-
ical discourse of HIV prevention, which relies on rationality and individual responsibility: “The 
unwillingness to discuss sexuality as anything other than essentially rational behavior is astonish-
ing. This unwillingness perpetuates a climate in which sexual activities that do not appear as ex-
pressions of individual self-interest tend to be pathologized” (Dean 2015a, S. 235). In this para-
digm, which is hegemonic in public health discourse in general, desire, fantasy, and community 
fall out of the picture of sex, which leads to unsatisfying accounts for gay risk-taking behavior. In 
the epidemiological public health perspective, having sex without condoms can be explained only 
through the framework of substance abuse, since no rational person would ever take such sexual 
risks.10 The fact that scientific biophysiological explanations are the only game in town and non-
scientific, cultural interpretations of sex are excluded from public health discourse is, according to 
Dean, useful to pharmaceutical industry, as it creates a demand for their products. This is an eco-
nomic intensification of what Foucault called scientia sexualis (Foucault 1978).11 
Second, Dean draws on Preciado’s Testo Junkie (Preciado 2013) and his concept of “pharmaco-
power”. Preciado holds that power nowadays works on the molecular level, through pharmaceutics 
                                                 
10 For different accounts of risky gay sex see Dean (2011) (psychoanalytical) and Halperin (2007, 2016) (against 
psychoanalysis). 
11 See Patton and Kim (2012) for a critique of PrEP trials which argues that they are following a pharmaceutical 
paradigm which cannot account for cultural prevention techniques. 
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which became an intrinsic part of sexuality: “Biopower gets inside us not only through psycholog-
ical mechanisms of identification (as we figure out who we truly are sexually), but also through 
the pharmaceuticals we ingest to become the sexual beings we aspire to be” (Dean 2015a, S. 237). 
Preciado builds his argument on pharmacopower by drawing a connection between the contracep-
tive pill for women and biotechnology for trans* people, such as hormones, to show that they both 
stem from the same biopolitical “sex-gender industrial complex” (Preciado 2013, S. 28). This com-
plex profoundly changes sexuality by technologizing it, allowing for new surveillance and control. 
Additionally, relying on pornography, which produces desire (Preciado 2013, S. 304), biopower 
today “has full access to our bodies and their desires in the services of economic profit” (Dean 
2015a, S. 239). PrEP has a profound impact on gay sexual subjectivity and desires, creating a new 
lust for condomless sex which is mediated through porn, pharma and public health (Dean 2015a, 
S. 239–241). Therefore, according to Dean, PrEP is just the next intensification of this economi-
cally driven biopolitical regime, and a new phase in the long history of the medicalization of gay 
sexuality.12 
Biopolitics in grand narratives of modernity. Contemporary Italian political theorists like Giorgio 
Agamben, Antonio Negri and Roberto Esposito make biopolitics a critical category for the analysis 
of modernity, loosely drawing on Foucault. In their works, biopolitics is the defining characteris-
tics of modernity. Agamben paints a dark picture of modern biopower as absolute sovereignty 
which controls biological life (zoê as opposed to bíos) and can reduce it to bare life, and argues 
that the concentration camp is the political paradigm of modernity (Agamben 2002). In contrast, 
Antonio Negri and Michael Hardt are optimistic that the “multitude”, a diverse resistance move-
ment or force without central control, can counter biopolitical exploitation in late capitalism (Hardt 
and Negri 2002, 2004; Pieper et al. 2007). Esposito, in turn, gives a more nuanced account of 
biopolitics as immunization, which can account for both its repressive and affirmative sides (Es-
posito 2010, 2011, 2013; Langford 2015). 
HIV has not been counted among the typical topics of these grand narratives about modern bio-
politics. Still, Jaako Ailio connects the biopolitical thinking of Roberto Esposito to an investigation 
                                                 
12 See Halperin (1990) for the creation of ‘homosexuality’ through medical discourse. 
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of HIV (Ailio 2013, 2017a, 2017b).13 In doing so, he aims to develop a concept of “liberal thana-
topolitics”, following Esposito’s concept of Nazi thanatopolitics. Esposito’s explanation of bio-
politics refers to the concept of immunity, which means destructive power (like the immune sys-
tem) that aims at protecting life or social institutions. However, immunity is a matter of degree; if 
there is too much of the protective power, it destroys what it is meant to protect. Following Espos-
ito, Ailio localizes a “deadly potential” (Ailio 2013, S. 261), i.e. the possibility of immunity turn-
ing into thanatopolitics, in liberalism and its subjective human rights regime. These rights are 
based on the juridical notion of the person, which is decoupled from the body. Ailio argues that 
only subjects count as persons, who have autonomous control over their body, which means that 
not all human beings count as persons (excluded is for example the madman, historically blacks, 
and contemporary refugees). Reducing some human beings to mere things is therefore intrinsic to 
the concept of the person and consequently, also to liberal human rights (Ailio 2013, 260f.). Re-
garding the liberal responses to HIV which aim at effective prevention and treatment, Ailio argues 
that the unequal distribution of access to treatment or prevention is an instance of liberal thana-
topolitics, however one that does not rely on a state of exception (Agamben 1998) but follows 
from the very logic of personhood. His argument emphasizes that two groups of people are ex-
cluded from the liberal form of personhood, and thus efficient HIV treatment: people in countries 
without fully functioning public health systems and beyond reach of aid-sponsored HIV programs, 
and undocumented migrants in the West without access to treatment and prevention services (Ailio 
2013, S. 261–264). 
PrEP is only mentioned once as evidence for the defeat of a conservative fight against treatment 
of HIV and for the hegemony of liberalism (Ailio 2013, S. 261). Following Ailio’s framework, 
one could argue that subjective rights are not the adequate political means to extend access to 
PrEP. Instead, using Esposito’s rather vague terms, PrEP access could be extended through the 
“community” (Ailio 2013, S. 265), which might translate here into public health policies which 
are not organized through rights and citizenship but open for everyone. Such a solution, however, 
could have been reached without the Überbau of Italian school’s biopolitical grand narratives. 
                                                 
13 See also van Doorn (2013), who builds his critique of PrEP on Agamben, Negri, and Esposito. While his point that 
community structures should be included in public health prevention strategies is plausible, van Doorn fails to explain 
why PrEP is a problem and how this is connected to biopolitics. 
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Nuanced Biopolitics. Nikolas Rose and Paul Rabinow stand for a more nuanced approach to bio-
politics, which is informed by Foucault and his concept of (bio-)power (Rose and Rabinow 2016; 
Rose 2007a; Rabinow 1999, 2005). In contrast to Dean and Ailio, these authors account for both 
the negative and affirmative sides of biopolitics through highlighting the capability of “biological 
citizens” to make ethical-political decisions on biopolitical questions (Rose 2007b, S. 259; Fassin 
2009). According to Rose, biomedical innovation neither leads to a utopian future nor to over-
whelmingly repressive pharmacopower, but to a multitude of small scale adaptations which sig-
nificantly change the way we understand our bodies and lives, and which are all subject to open 
biopolitical struggles. What was regarded as ‘natural’ in the past becomes an object of possible 
interventions, changing the oppositions of nature vs. culture, normal vs. pathological, and treat-
ment of illness vs. enhancement of capacities, thereby opening up new possibilities of and the need 
for political deliberation about the worth of different forms of life (Rose 2007b, 253f.): “Our bio-
logical life itself has entered the domain of decision and choice; these questions of judgment have 
become inescapable. This is what it means to live in an age of biological citizenship, of ‘somatic 
ethics,’ and of vital politics” (Rose 2007b, S. 254). This somatic ethics, for Rose, is closely linked 
to biocapital. Biomedical intervention is both open for capitalization through pharmaceutic com-
panies, which need ethical approval by professional bioethical experts, often philosophers, who 
are dependent on grants and research money. On the other hand, biopolitical struggles require both 
actors in the pharmaceutical industry as well as patients and activists to think ethically about their 
choices and everyday actions in relation to different biomedical knowledges and experts. As a 
result they will build new normative expectations based on these technologies and become experts 
themselves (Rose 2007b, S. 257).14 
HIV/AIDS activism is an example of such biological citizenship, illustrating what Rose terms “bi-
osociality”. AIDS patients and activist came together in communities, performing numerous func-
tions such as spreading information, campaigning for rights regarding treatment and quality of life 
and fighting societal stigma, and claiming a voice in the development of medical expertise (Rose 
2007b, S. 144; Epstein 2009). The activist and the traditional medical community who started off 
as antagonists soon formed an alliance: This enabled medical professionals to reach their target 
                                                 
14 See for patient activism Epstein (2016); Novas (2016). 
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community of gay men, and in turn the activists became decisive actors in the further development 
of medical expertise and safer-sex advice. 
The concepts of biocapital, biosociality, biological citizenship, and somatic ethics offer a good 
toolbox to describe and frame the debates surrounding PrEP. The concept of biocapital denotes 
the capitalist logics of Big Pharma and the politics behind pricing and patents, which antagonize 
the interests of patient communities and public health providers. The concept of biosociality refers 
to the fact that a community of (potential) PrEP users isconstituted through their risk of infection. 
Biological citizenship is the act of claiming active rights and the empowerment of a policy making 
community. In fact, the main drivers for the development of PrEP were public health and the gay 
community, and not Big Pharma.15 Somatic ethics refers to the ethical practices surrounding PrEP. 
Because PrEP enables certain practices, especially condomless sex, which are often morally sanc-
tioned, it constitutes a specific case in which somatic ethics are highly contested. In fact, the bio-
sociality of PrEP does not just stem from biological traits or illness (as in classical patient activ-
ism), or the risk of illness connected to unalterable sexual orientation (as in classical HIV activ-
ism), but it is a specific sub-group of gays who engage in ‘high-risk’ sex practices, and this en-
gagement is often conceptualized as ethical choice. 
 
4 The Political Debate Around PrEP 
I propose to schematically distinguish four positions in order to map the current debate around 
PrEP. To do so, I will reconstruct the rationality of positions which can be found in the field, i.e. 
in statements of activists, scholars, medical professionals, and community members, and explicate 
the relations between them. Loosely following Foucault’s analysis of discourse and power, the 
reconstruction focuses on the struggles about norms of sexuality, sexual subjectivation and sub-
jectivity, and homophobia (Foucault 1971, 1978). The mapping is further informed by the biopo-
litical literature reconstructed above and highlights biopolitical aspects of PrEP. This allows to 
evaluate the biopolitical approaches regarding their analytical and normative potential and lay 
grounds for the claim that PrEP should be interpreted as ‘democratic biopolitics’. I do not claim to 
                                                 
15 The big initial PrEP studies were financed by public health institutions and not by pharma companies, see fn. 25. 
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capture all positions on PrEP which have been articulated. However, this schematic mapping 
brings, I argue, specific lines of conflict to the forefront. These emphasize among others how the 
biopolitics of PrEP intersects with homophobia and heteronormativity on the one hand, and the 
real or potential democratic nature of political debates around PrEP on the other.  
The four positions outlined here are (1) gay pro-PrEP, (2) gay anti-PrEP, (3) professional pro-
PrEP, and (4) professional anti-PrEP. On the one hand there is the gay perspective and the debate 
within the gay community between pro-PrEP and anti-PrEP camps. On the other hand, there is the 
non-gay perspective of medical professionals and the general public. Here again, a pro-PrEP and 
anti-PrEP perspective can be found. Some of these perspectives relate to specific theoretical ap-
proaches to biopolitics as reconstructed above. Some theoretical elements of the governmentality 
perspective, for instance, can be found in the gay critique of PrEP, for example, that pharmapower 
is pressuring gays to use the medicine. Pro-PrEP gays, however, invoke arguments about gay sub-
jectivity which are not represented in the debate on biopolitics. The political activity of gay PrEP 
activists as biopolitical citizens fits well into Rose’s and Rabinow’s biopolitical perspective. The 
pro-PrEP medical position puts the emphasis on ‘effectiveness’ regarding prevention rates, finan-
cial aspects, and quality of life. Compatible with this argument is the critique of the inequality of 
access to HIV drugs through the framing of rights, which is the outcome of Italian Theory’s grand 
narratives on biopolitics applied to PrEP. Some anti-PrEP medical professional arguments are sim-
ilar to the pharma-skepticism of governmentality studies, and are based, at least in Germany, on 
an aversion against medicating healthy bodies which stems from a naturalist attitude. Homophobia 
and homonormativity,16 which are not accounted for by biopolitical theories, play a crucial part in 
my mapping and reconstruction of the debate. Nevertheless, the related fight about good or bad 
ways to be gay and to have gay sex can be understood as a fight about somatic ethics, drawing on 
Rose’s work. 
                                                 
16 The concept of homonormativity describes and criticizes the conservative normativity of mainstream gay politics 
which is focusing on monogamous couplehood, marriage and domestic consumerism. Homonormativity, in difference 
to queer critique, does not contest, but stabilize heteronormativity, i.e. the belief that heterosexuality is a natural norm 
and the support of institutions of heterosexuality, sexism, and patriarchy, such as marriage. Homonormativity also 
constitutes a difference between ‘good’ and ‘bad’ gays and thereby leads to new forms of (internalized) homophobia, 
see Duggan (2002) and Murphy et al. (2008). 
14 
The pro-PrEP gay perspective has two sides. On the one hand, many gays are informed about the 
medical and public health advantages of PrEP and draw on them to argue in favor of PrEP. I will 
elaborate on these arguments when I describe the non-gay medical-professional pro-PrEP posi-
tion.17 On the other hand, there is a non-medical argument for PrEP, which draws on the signifi-
cance of PrEP for gay subjectivity and experience (Auerbach and Hoppe 2015). I will reconstruct 
this argument first, which falls into Rose’s category of somatic ethics. More precisely, I propose 
to call what is at stake here sexual-somatic ethics: the negotiation of politics, subjectivity, sexual 
pleasure and desire, sexual norms, and medical technologies. The starting point is that sex without 
condoms is simply better than sex with condoms. However, even an utterance of this banality is 
dangerous in a climate of moralized sexuality. It is a statement which does not operate in the realm 
of reason and responsibility, but ‘merely’ in the realm of desire and lust. The immediate reaction 
to this statement by most people is that it is irresponsible, given the dangers of condomless sex 
and the relatively small effort it takes to use a condom. This immorality judgement is reinforced 
when considering the supposed higher risk of infecting others with STIs when engaging in con-
domless sex. Desire and lust are not strong arguments in this discourse on responsibility, reason, 
and guilt. Prevention, within this paradigm, exclusively means to inform people about certain risks, 
assuming that this will lead them to make ‘rational’ choices during sex (i.e. use a condom).18 
This resistance against the demand to enjoy condomless sex shows something more deeply prob-
lematic in the current state of gay sexuality and subjectification – and PrEP is seen by many gays 
as an answer to this more fundamental problem. Obviously, blatant and open homophobia is a 
major problem, which has even been reinforced in the last couple of years in the West due to the 
rise of right-wing movements, who are presenting homophobic hate-speech as a legitimate position 
in public discourse.19 However, even within diversity-affirmative liberalism, where homophobia 
                                                 
17 The distinction between the gay and non-gay medical perspectives collapses to some degree, as many HIV medical 
experts are gay and HIV research developed partially out of the gay community’s HIV activism. 
18 For a critique of this rationalistic paradigm which leaves out gay experience, subjectivity, fantasy, sex and desire, 
see Adam (2011), Race (2012), Dean (2011, 2012, 2015a, 2015b), Halperin (2016), Trachman and Girard (2018). 
19 In Germany, for example, there is a correlation between the growing political power of the homophobic right-wing 
populist party AfD the rise of homophobic attitudes (LSVD n.d.; Decker and Kiess 2016, S. 51), and the rise of 
homophobic hate crimes (Beiker 2017), which many actors interpret as a causation (LSVD 2017). A social and polit-
ical movement against gender equality, sexual emancipation and self-determination with many personal and thematic 
overlaps with right-wing movements and parties became more outspoken and powerful in Europe over the last years, 
c.f. Hark and Villa (2015); Kuhar and Paternotte (2017). Some Westeuropean right-wing parties define tolerance for 
different lifestyles as ‘European’, to reject Muslims, Islam, and people of color as homophobic and uncivilized. It is 
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seems to be absent and gays are happily married, homophobia deeply structures gay subjectivity 
and sexuality. It is ok now to be gay, but only if you are a ‘good gay’. If one lives a normalized, 
bourgeois and successful life, a life of homonormativity which follows heteronormative rules, gay-
ness does not matter. This acceptance of bourgeois gayness is a success of the gay movement 
which was achieved by fighting the stereotypes of hypersexualized and effeminate gays through 
presenting and behaving as ‘normal’, masculine, and desexualized – this is homonormativity. 
Mainstream gays present their sexual orientation as an accidental, instead of essential, property of 
their personality; it does not determine who they are. With gay marriage, this journey to normali-
zation reached its peak, and many gays are just behaving like straights nowadays, and are happy 
to receive social recognition and acceptance for it. But this acceptance comes at the price of a new 
exclusion. Trans* and gender non-conforming people, queers of color, and gay men who engage 
in different sex than with one stable partner in a long-term romantic relationship are excluded from 
this homonormativity (Flores 2017). 
While gay pride of the ‘good gays’ is the surface of contemporary liberalism, the gay shame of the 
‘bad gays’ is its flipside (Halperin and Traub 2009). This creates a constellation of shame and guilt 
surrounding gay sex (Hequembourg and Dearing 2013). The AIDS and post-AIDS generations 
grew up with a deep fear of gay sex (Cain 2017; P. 2015). It was not only something shameful, but 
also something dangerous. Engaging in it was problematic enough but engaging in it in an ‘unrea-
sonable’ and frivolous way and getting infected with HIV or other STIs pushes gays outside of the 
framework of liberal acceptance of homosexuality. While guilt is not assigned anymore for being 
homosexual, it is even more assigned for engaging in non-normative and ‘irresponsible’ sex. 
Therefore, gay sex is constituted around an economics of guilt which stems from the liberal and 
homonormative refinement of homophobia, of which condoms are an essential part.20 Condom 
adherence is the perfect guilt tool, and many gays report psychic self-tortures after having forgotten 
to use them, not only because of the fear of an infection, but because of the stigma related to the 
                                                 
important to note that this seemingly gay-friendly rhetoric is used only instrumentally for promoting anti-muslim 
racism (Siegel 2017). Queer organizations fight against this instrumentalization of their cause for racist projects and 
point out that homo- and transphobia is a general problem in society. It is not specific to Muslims, but rather promoted 
by (right-wing) anti-egalitarian ideologies. See for example GLADT (2009). 
20 Race (2016) describes the anti-PrEP attitudes in the community as a fear of sex. 
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supposed irresponsible behavior, to which an infection would be attributed. Under this rubric, con-
dom based gay sex is intrinsically linked to guilt, fear, and internalized homophobia. PrEP is a 
new chapter in the queer fight against homophobia and finally helps to disentangle gay sex from 
its connection with illness and death, which it had for about 40 years now (Collins et al. 2016; 
Koester et al. 2017; Grace et al. 2018; Gilbert 2018).21 
The liberating aspect of PrEP is not only about homophobia and social stigma, but it also changes 
and eases the dynamics of gay sexuality: PrEP reduces the need for constant negotiation of illness 
during gay sex. In order to act responsibly and to deflect guilt in the sexual paradigm of condoms, 
fear and guilt, gays have to be constantly aware of risk and negotiate it.22 They have to make 
assumptions about how ‘dangerous’ the partner is and if they can trust them. Especially the bottom 
(the receptive partner in anal intercourse) has hardly any control about the use of condoms, and 
has to check manually sometimes during the intercourse if the condom is still in place (Danan 
2018). Thus sex is constant worrying for many gays. PrEP can change this condition. In terms of 
responsibility, this means that for the first time one can efficiently take responsibility by shifting 
it to adhering to the drug regime, away from the often-uncontrollable dynamics of sex. Here is an 
open contradiction to Dean’s position, who does not interpret this shift of responsibility as liber-
ating, but as an intensification of the rationalization and disciplining of sexuality, as for the first 
time, responsibility can be objectively measured through drug levels in the blood (Dean 2015a, 
S. 233).  
Thus sexual ethics, social norms, and (medical) technology are intertwined and form a nexus of 
power. Building on Rose’s term somatic ethics, this sort of ethical problematization can be called 
sexual-somatic ethics. It is a reflection and further development of community norms, personal 
choices, and desires, which is negotiating medical technology.  
The anti-PrEP gay perspective also comprises medical arguments on the one hand and arguments 
which address subjectivity, sexual norms, and politics that fall under the rubric of somatic ethics 
on the other. As above, I will only reconstruct the ethical arguments here, discussing the medical 
                                                 
21 Exemplary for this liberating function of PrEP for gays in relation to guilt and condoms is a public post on Facebook 
(in German), which was widely shared, cf. Hartmann (2017). 
22 Regarding the negotiation of responsibility see Young et al. (2016). 
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arguments which are used by gays along with the non-gay medical professional and public debate. 
Gay opponents against PrEP argue that it significantly changes gay sexuality and fosters a culture 
of condomless sex which effectively limits the freedom of those who want to use condoms. Many 
reports and complaints by gays in major Western cities, where PrEP prevalence is already high, 
show that it became more difficult to organize hook-ups through apps when insisting on condom 
use (Holt et al. 2018). Sex is a cultural practice and participants are subjectivated into a sexual 
culture. There is no essence of good and natural sex, instead it is always mediated through norms 
and technology. Before PrEP, condom-usage was a standard and unquestioned norm, and thus 
accepted as non-intrusive for many gays, even though condom adherence was a problem for a 
significant number of gays (Dean 2011; Halperin 2007, S. 11–37). The possibility for HIV-risk-
free condomless sex changes this sexual subjectification. The condom is put into question and 
becomes the object of a battle of sexual ethics, where many desire condomless sex and others 
defend the condom as only means for safe sex. The sexual subjectification towards condomless 
sex is seen by many as a pressure to take PrEP as well, even if they do not really want to. PrEP 
might become the new norm, to which one has to adhere in order to participate in the changed 
sexual culture.  
Anti-PrEP gay arguments draw also on reasoning in line with governmentality studies’ biopolitical 
critique. Even when they do not refer to Foucault and the term ‘subjectification’, the critique I 
reconstructed above can be captured by this concept. Some connect sexual subjectification, i.e. the 
changed community norms and the pressure on individuals they entail, to public health authorities 
and the pharma-industry. The argument is that PrEP is promoted by pharmaceutical companies in 
order to build new markets and exploit PrEP-users economically by changing sexual subjectifica-
tion. Obviously, the pharmaceutical industry appreciates non-infected people taking drugs, as they 
outnumber the infected (Thissen 2014; Behnke et al. 2014). In this regard, PrEP inscribes itself in 
the general trend of medicalization and especially pharmaceuticalization (Bordogna 2014) of pre-
vention. However, such arguments overlook that the development of PrEP was in fact spearheaded 
by an interaction between the gay and public health communities through the early integration of 
the gay stakeholders in the processes of the three most important PrEP-MSM-studies iPrEx, 
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Ipergay, and Proud (Cairns et al. 2016, S. 2).23 The initial MSM-PrEP studies were not financed 
by Gilead, who only donated the drugs and placebos, but by government sponsored research insti-
tutes.24 
Next to concern about the change of sexual-somatic ethics and PrEP as project of Big Pharma to 
exploit gays, there also exists a straightforwardly hateful homophobic stigmatization of PrEP users 
inside the gay community (Calabrese and Underhill 2015; Grace et al. 2018). It is the intra-com-
munity version of the homophobic guilt and shame economics of sex that leads to the homonorma-
tive construction of good gays and bad gays, as described above. One example for this PrEP-
shaming is the word “Truvada Whores”, which was used as hate-speech against gays on PrEP, 
referring in an abjecting way to their supposed promiscuous sexuality (Duran 2012). In an act of 
typical gay re-iteration, this concept was quickly re-appropriated (Galinsky et al. 2013) by pro-
PrEP gays and PrEP-users and turned into a self-identification that signifies pride and the criticism 
of social stigma and slut-shaming (bones 2014; Duran 2014). The clearest instantiation of hate-
speech against PrEP can be found on online hook-up and dating network communication. The 
following citations are extracted from screenshots of online dating conversations which I received 
from PrEP activist Emmanuel Danan in Berlin (Danan 2018). They clearly show HIV and PrEP 
stigma in the gay community (Trigger warning: Hate speech and explicit language!). The insults 
are often constructed in the language of responsibility and based on misinformation about the 
medical technology, its efficiency and risks. They show how important it is for gay guys to be on 
                                                 
23 Nevertheless, there are significant problems with some PrEP studies, which stem from global capitalism and 
pharma profit interests. Especially the Partners-Trial Baeten et al. (2012) is problematic because of offshoring, con-
ducting risky trials in poor countries of the global south (here in Uganda and Kenya) to develop drugs to treat patients 
in the global north. Another problem with the Partners-Trial was that it transferred drugs from HIV positive patients 
who needed them the most to HIV negative persons for the use as PrEP, cf. Patton and Kim (2012). First PrEP studies 
in Cameroon and Cambodia in the early 2000s were stopped due to violations of ethical standards which put partici-
pants at risk of infection, after Act Up Paris protested against the trials, see Singh and Mills (2005). 
24 The iPrEx-Study was mostly financed by the U.S. National Institutes of Health (NIH) (Grant et al. 2010), the 
Ipergay-Study mostly by the French Agency for Research on AIDS and Viral Hepatitis (ARNS) (Molina et al. 2015), 
and the PROUD-Study was mostly financed by the British Medical Research Coucil Clinical Trials Unit at University 
College London and Public Health England (McCormack et al. 2016). The presently running Discover-Study is com-
paring Truvada and Descovy and is fully sponsored by Gilead (AVAC 2018). Descovy is a slightly modified version 
of Truvada, which is supposed to have less side-effects. Gilead needs to prove the advantages of Descovy over Truvada 
in order to keep profits high after the patent of Truvada recently run out, which opened the market for cheaper generics 
of Truvada. 
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the ‘good’ side, a desire which is sadly often enacted through stigmatizing others for their sexuality 
and their (well informed) prevention choices:25 
“You’re making the responsible people pay for what the unresponsible people are doing.” 
“Oh look, one of those fags that’s proud to be a who’re! Lol. Gay pride!!” —Answer: “I shall 
take that as a compliment & move on with my evening”— “Lol ok whore” 
“Go fuck Poz guys you sicko. Your gross as fuck. I keep blocking you but you keep making 
new profiles. No one cares if your on pRep. Ok” 
“Neg on prep = HIV + = go away” 
“Prep. Fuckin disgusting. Dirty breeder. Prep is to stop HIV only. Not other vile STD” 
“Hi treibe es nicht mit Leuten die prep. Nehmen Zu risky. Syphilis und so.. sorry.” —Answer: 
“Auch ne Einstellung.”— “Ja bin Vorsichtig U d mit meiner Einstellung bin ich nicht allein. . 
sorry. Prep Leute sind für Menschen 2 Ter Klasse . Jo alles gute” 
“baresex ist jedenfalls unverantwortlich. wird Zeit daß die AFD Listen anlegt mit Leuten wie 
dir und sowas eingesperrt wird. Sicherungsverwahrung oder Endlösung” 
 
Despite this heavy HIV and PrEP stigma and the related hate speech, there are also good news: 
The increased use of PrEP already leads to measurably less HIV and PrEP related stigma in gay 
online dating (Golub et al. 2018). This supports the gay pro-PrEP argument that PrEP can have a 
liberating effect for gay sexuality. 
The pro-PrEP professional perspective points out that PrEP is a useful, efficient and cost-effective 
tool to lower infection rates of vulnerable populations and therefore a necessary component in a 
strategy to fight and finally end HIV/AIDS. As the efficiency of PrEP is unquestioned today, I will 
                                                 
25 I extracted the texts of the chats exactly as they appear on the screenshots. 
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focus on two problems raised by PrEP-critics and PrEP-supporters’ answers to these: The potential 
spread of other STIs because of increasing rates of condomless sex and the problem of financing. 
One argument against PrEP is the assumption that it leads to the spread of more sexually transmit-
ted infections, as it fosters a culture of condomless sex, for which there is some evidence (Nguyen 
et al. 2018). The argument of medical professionals and gay PrEP activists against this fear is that 
first, condoms do not work well in preventing the other STIs (mainly gonorrhea, chlamydia, syph-
ilis), so that the difference in infection rates is not significant. Second, on the contrary, PrEP helps 
in the fight against these other STIs, as it leads many vulnerable people to get tested for these STIs 
regularly, as the PrEP regime requires a general sexual health check up every three months (Scott 
and Klausner 2016; Montano et al. 2017). Public health spends a lot of energy to get vulnerable 
people to get tested, but outreach to the community is difficult, especially within a rationalist sex-
education paradigm. With PrEP, people who are particularly at risk (with or without PrEP) for 
STIs come to doctors in order to get tested out of their free choice in order to get the PrEP drugs. 
The second concern around PrEP is that it is expensive. However, several studies show that it is 
cost-effective if given to vulnerable populations, because the costs of the lifelong treatment of an 
infected person are far higher than the costs for PrEP (Juusola et al. 2012; Schneider et al. 2014; 
Cambiano et al. 2018; Shen et al. 2018). 
The major concern of public health professionals nowadays is the unequal distribution of PrEP 
among vulnerable communities. While PrEP is more and more accepted and welcomed in gay cis-
gendered populations of privileged social status, men who have sex with men (MSM) but do not 
identify as gay, transgender people, gays of color, straight black men and women, and migrants 
are particularly vulnerable to HIV in many countries but do not have easy access to PrEP (Ayala 
et al. 2013; Land 2017; Sevelius et al. 2016; Elopre et al. 2017; Page et al. 2017; Villarosa 2017). 
This is in part because sex education programs are framed on rationality, risk management, and 
individual responsibility and do not speak to vulnerable communities (van Doorn 2013). Further-
more, the regular adherence to PrEP is based on an identification as somebody who is at risk of 
becoming infected with HIV. While this identification is already charged with stigma in gay com-
munities who have been dealing with HIV for more than three decades, it is no surprise that in 
communities in which HIV is not an ongoing topic, such an identification is even more difficult. 
A related problem are the still enormous costs for HIV drugs, as pharma companies are creatively 
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using legal frameworks and patents for maximizing profit, contrary to the interest of patients, po-
tential PrEP-users, and the general public. This is especially scandalous given that the major PrEP 
studies were financed by public research institutes (Summers 2018).  
The anti-PrEP medical and general public perspective invokes PrEP criticism which I described 
above and which is tackled by arguments and studies from the pro-PrEP side. Five further argu-
ments are made against PrEP, which I discuss now: First, a general skepticism towards the idea of 
medicating healthy bodies, given potential side effects; second the possibility that Truvada re-
sistant HIV strains might develop; third the problem of drug adherence, fourth specific institutional 
boundaries in public health systems, which I will illustrate with the example of Germany; and fifth 
the homophobic argument that the general public should not pay for the pleasure of gays. 
Many medical professionals, especially if they are not HIV specialists, are skeptical about the idea 
of medicating healthy bodies for prevention purposes. They argue that even though users hardly 
experience side effects, Truvada is still a heavy drug which affects kidney, liver, and potentially 
bone integrity. What is more, it is possible that Truvada has long-term side effects which are still 
unknown (Wood 2012). This attitude towards medicalization may be culturally rooted. A skeptical 
attitude is more prevalent in Germany than in the United States. Public attitudes in the U.S. towards 
pharmaceuticals and biomedical technology can be described as pragmatically open, while Ger-
mans are rather skeptical of (bio-)technological interventions in bodies and nature (Meulemann 
2005; Schöne-Seifert 2005). Second, while researches discuss the possibility that Truvada-re-
sistant HIV strains might develop and control for such a development in studies, so fare no resistant 
strains occured (Delaugerre et al. 2018). Third, low drug adherence is a problem all studies point 
to. However, this does not lead to many seroconversions, as Truvada is also effective on low ad-
herence rates, so that adherence levels are generally high enough to enable prevention (Haberer 
2016; Closson et al. 2018). However, adherence remains a crucial factor and needs to be tackled 
by PrEP programs. 
Fourth, a specificity of the German healthcare system is that statutory health insurance generally 
does not cover drugs as prevention, which is why currently PrEP is not paid for by public insur-
ances. The board which decides about the payment schemes (Gemeinsamer Bundesausschuss) 
claims – contrary to medical evidence – that behavioral prevention (condoms) works for everyone, 
and that therefore prevention is a matter of individual responsibility (Aidshilfe 2016). One strategy 
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of German PrEP activists was to pursuade individual health insurances to cover the drugs, arguing 
that this might increase their popularity among their customers. In this rationale, German insurance 
providers already today offer a huge range of lifestyle and wellness treatments like homeopathy, 
which, unlike PrEP, are not proven to be effective. Very recently, the German Health Minister 
announced that PrEP shall be regularly provided by public health insurances (Bundesministerium 
für Gesundheit 2018). Fifth, homophobic attitudes prevail among medical professionals and the 
general public. Stereotypes of promiscuous gay men who rightfully suffer for their lifestyles are 
still common – and lately rising due to the influence of right wing populist in Europe and the 
United States.26 PrEP is seen as related to a choice of risky sexuality, which is imagined as im-
moral and therefore should not be sponsored by the general public.27 This homophobic rationale, 
which stresses the individual responsibility for behavioral prevention, ignores the fact that the HIV 
epidemic targets gays, trans* persons and people of color, who are all underprivileged minorities 
that deserve public help. Furthermore, as the scale of the HIV epidemic nowadays is due to the 
blatantly homophobic reaction in the 1980s (which was, far and foremost, a non-reaction leading 
to the death of millions), one needs to move beyond individual responsibility and turn to redressing 
past injustice by providing effective prevention programs nowadays.  
 
5 The Democratic Biopolitics of PrEP 
The case of PrEP shows the complexity of contemporary biopolitics. PrEP is an instantiation of 
current biopolitics, combining public health concerns, conceptualizations of normality, and ethics 
of sexuality, while being part of a larger trend towards medicalization in general and the medical-
ization of sex in particular (Cacchioni and Tiefer 2012). What is especially visible in the case of 
PrEP is the connection between community sexual norms, sexual (medical) technology, and ho-
mophobic stigma. PrEP is a dispositive which changes sexual subjectification, and it is primarily 
                                                 
26 See fn. 20. 
27 Two examples of this widespread homophobic discourse are the comment of a local German newspaper regarding 
the announcement to cover PrEP by German public insurances and the user comments of an earlier article on PrEP on 
the mainstream German news website Spiegel Online, cf. irb/dpa (2017); Queer.de (2018). 
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this change which is contested and fought for both from a perspective of gay subjectivity and from 
a medical professional perspective. 
The mapping of the debate showed that different biopolitical approaches have specific strenghts 
and weaknesses when applied to PrEP. The existing biopolitical literature is connected to the cur-
rent debate on PrEP on two levels, normative and analytical: Biopolitical theory can inform a po-
sition towards PrEP and account for what is going on in the debate about PrEP. The two evaluative 
biopolitical schools, governmentality studies and Italian Theory, when applied to the case of PrEP, 
offer arguments which are also put forward in the debate. A position similar to Dean’s critique of 
the repressive side of pharmacopower and its connection to capitalist interests can be found in 
some PrEP critical statements, and Ailio’s argument for the extension of access to HIV treatment 
independent of subjective rights could support HIV medical professionals’ demand for better HIV 
drug supply for vulnerable communities. In both cases, however, only superficial theoretical ele-
ments of biopolitics are used which does not improve the political conversation. From the PrEP 
activism perspective, Dean’s critique seems far-fetched and sounds like conspiracy theory, and is 
not doing justice to the actual struggles, while Ailio’s demand is trivial and would not have needed 
Esposito’s biopolitical Überbau of a grand narrative of modernity. 
The nuanced biopolitics account represented by Rose and Rabinow and connected to the scholar-
ship of patient activism, offers a theoretical framework to better understand the complexities of 
the politics around PrEP. It accounts for the bioeconomic interests of pharma companies, the dis-
cursive shifts towards medicalization in the health sector, and the agency of and complex inter-
connections between professionals, users, patients, and activist. Criticizing dark visions of over-
whelming biopolitical and pharmacopower, as put forward by Dean among others, Rose points out 
that biopolitics and the implementation of new medical technology involve complex political ne-
gotiation of somatic ethics and many different actors who engage in biopolitical citizenship. The 
political debate around PrEP is an instantiation of such a complex negotiations, which I may call 
democratic: The democratic biopolitics of PrEP. The process of democratic negotiation requires 
four questions to be answered: 
First, the questions of representation, power, and interest at stake: Who is allowed to decide about 
desirable preventative technologies and who is allowed to be heard? Who finances prevention and 
who profits? Second, different sexual-somatic ethics, i.e. the ways to organize the sex norms of 
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communities in relation to medical technologies, are problematized and require negotiation. Dif-
ferent ethical choices clash (i.e., pro-condom vs. anti-condom), and compromises should be 
reached because the hegemony of the one is threatening the other. Third, negotiations must con-
sider the boundaries of democratic discourse. These boundaries are often violated in the discussion 
around PrEP, when homophobic and slut-shaming hate speech is used by both gay and non-gay 
actors. This hate speech not only stems from individual’s intentions, but from social structures: 
Heteronormativity (the discursive hegemony of heterosexuality and cis-gender) and homonorma-
tivity (the differentiation between good gays and bad gays). Therefore, political education and 
anti-discrimination work is needed to change these attitudes and make people ready for the demo-
cratic exchange about PrEP. This involves the complex negotiation of actors’ freedom and poten-
tial political paternalism, as political education is itself normalizing (Schubert 2018). Fourth, PrEP 
evokes democratic questions about the rationality of legitimate discourse, as on the one hand, ir-
rational, medically misinformed, and hateful speech is one of the central problems in the debate. 
On the other hand, one major deficit of prevention outreach and sex-ed campaigns is that they 
often rely on a rationalist paradigm, which supposes that more information lead to less risky sex, 
and that sexual practices are controlled by conscious and rational actors. Successful PrEP programs 
are reasonably (i.e., based on medical evidence) moving beyond this rationalist sex-ed paradigm 
by accounting for the irrational aspects of sex, i.e. fantasy, desire, and subjectivity. Unlike classical 
deliberative democratic theories, which exclude unreason, the democratic biopolitics of PrEP make 
unreason – sexual desire and subjectivity – the starting point of political deliberation. The demo-
cratic biopolitics of PrEP confirm democratic theories which argue that democratic reasoning de-
pends on processing and deliberating its other, unreason or irrationality (Menke 2015). 
To frame PrEP as a problem of democratic biopolitics not only helps to account for the complexity 
of the ongoing debate, but also allows to highlight paths to further democratization. Such a democ-
ratization requires to acknowledge that desire is not given, but a result of sexual subjectification 
through sexual-somatic ethics which are influenced by medical technologies and public health 
programs. If these processes occur unnoticed, negotiating them democratically is difficult. Making 
them explicit helps furthering democratic discourse. This would also allow tackling the underlying 
problem of homophobia on a large scale through political institutions such as education and law. 
Strengthening the position of (potential) PrEP users as most important stakeholders in the debate, 
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by including them in public health policy decisions, is of major importance. Finally, democratiza-
tion would entail the renegotiation and minimization of costs and profits in the health sector, which 
are backed up by international patent law, in order to create affordable access to PrEP for those 
who need it. 
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